Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.

RIDRUEJO E; PÉREZ PS; DI LELLO FA; CAMPOS RH; CULASSO ACA; GARCÍA G; ROMANO V; MARTÍNEZ AP; RIDRUEJO E; PÉREZ PS; DI LELLO FA; CAMPOS RH; CULASSO ACA; GARCÍA G; ROMANO V; MARTÍNEZ AP

VIRUS RESEARCH

ELSEVIER SCIENCE BV

Lugar: Amsterdam; Año: 2017 vol. 15 p. 140 - 146

0168-1702

Incorporation of direct acting antivirals (DAA) in the treatment of Hepatitis C Virus (HCV) significantly increases sustained virologic response rates. However, despite the greater potency offered by these antivirals, drug resistance plays a key role in patients with failure to DAA. Nevertheless, there is no information about the prevalence of resistance-associated substitutions (RASs) in Argentina. The aim of this study was to analyze HCV variants resistant to protease inhibitors (PI) in naïve patients infected with HCV genotype 1 from Argentina. In this retrospective cross-sectional study, 103 patients infected with HCV-1 were included. Eighteen positions related with RASs were analyzed by Sanger at baseline and phylogenetic analysis was performed to determine the diversification of this samples. The analyzed RASs were present in 38 out of 103 patients (36.9%) infected with HCV-1. Patients infected with subtype HCV-1b had higher prevalence of baseline RASs than patients infected with HCV-1a [51.6% vs. 12.8%, respectively (p